Using magnetic markers to locate breast cancer and lymph nodes after chemotherapy
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
This study is testing if using tiny magnetic seeds can help doctors find and remove breast cancer and lymph nodes more accurately in patients after they have chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05427071 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of using magnetic seed localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant chemotherapy. Eligible patients will have magnetic seeds placed in their breast tumor and lymph nodes before starting chemotherapy. After treatment, imaging assessments will guide surgical planning, allowing for breast-conserving surgery or mastectomy with targeted axillary dissection. The study aims to improve surgical outcomes and minimize unnecessary procedures.
Who should consider this trial
Good fit: Ideal candidates are patients with cT1-3N1 invasive ductal carcinoma who are planned for neoadjuvant chemotherapy.
Not a fit: Patients with distant metastasis, inflammatory breast cancers, or those who have had previous axillary surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise surgeries and better outcomes for breast cancer patients.
How similar studies have performed: Other studies have shown promise in using magnetic localization techniques, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy * mentally competent to give informed consent * Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy * Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy Exclusion Criteria: * Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers * History of previous ipsilateral axillary surgery or irradiation * Hypersensitivity to dextran compounds or iron * Iron overload disease * Pregnant or lactating patients * Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder * Mentally incompetent patients
Where this trial is running
Hong Kong
- University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Chi Mei Vivian Man, FCSHK, FRCSEd
- Email: vivian27@hku.hk
- Phone: 852-25898116
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.